Lv1
100 积分 2024-09-06 加入
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
3小时前
待确认
Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
2个月前
已完结
Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice
5个月前
已完结
Potential future direction of measurable residual disease evaluation in multiple myeloma
5个月前
已关闭
Potential future direction of measurable residual disease evaluation in multiple myeloma
5个月前
已关闭
Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice
5个月前
已完结
Diagnosis and Management of Multiple Myeloma
5个月前
已完结
How I manage mantle cell lymphoma: indolent versus aggressive disease
7个月前
已完结
Challenges in chimeric antigen receptor-T cell product administration in a high tumor-burden elderly patient with mantle-cell lymphoma
7个月前
已完结
Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
7个月前
已完结
皖公网安备34019202002308
